Veravas and Phanes Biotech Partner to Develop Blood-Based Alzheimer’s Diagnostic Test
Slice of Healthcare Team
Nov 12, 2024
Key Highlights
- Veravas partners with Phanes Biotech to co-develop a blood-based Alzheimer’s diagnostic.
- New test uses VeraBIND™ technology to detect tau pathology for early disease intervention.
- Affordable, accessible alternative to tau PET imaging, enabling diagnosis in early disease stages.
- Targets 92% of mild cognitive impairment cases that remain undiagnosed.
Source: Business Wire
Notable Quotes
“ Scientific discovery and therapeutic development in Alzheimer’s disease are surging, offering clinicians viable new opportunities to intervene early, potentially slow Alzheimer’s disease progression, and improve quality of life for patients. ”
Khalid Iqbal, Ph.D., Chief Scientific Officer at Phanes Biotech
“ Our technology has the potential to eliminate the uncertainties and accessibility hurdles of current Alzheimer’s disease diagnostics for the benefit of clinicians diagnosing and treating AD, their patients, and researchers conducting clinical trials. ”
Josh Soldo, Chief Scientific Officer at Veravas
